ACCURETIC Drug Patent Profile
✉ Email this page to a colleague
When do Accuretic patents expire, and what generic alternatives are available?
Accuretic is a drug marketed by Pfizer Pharms and is included in one NDA.
The generic ingredient in ACCURETIC is hydrochlorothiazide; quinapril hydrochloride. There are thirty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; quinapril hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ACCURETIC?
- What are the global sales for ACCURETIC?
- What is Average Wholesale Price for ACCURETIC?
Summary for ACCURETIC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 128 |
Clinical Trials: | 3 |
Patent Applications: | 3,117 |
Drug Prices: | Drug price information for ACCURETIC |
What excipients (inactive ingredients) are in ACCURETIC? | ACCURETIC excipients list |
DailyMed Link: | ACCURETIC at DailyMed |
Recent Clinical Trials for ACCURETIC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Ranbaxy Laboratories Limited | N/A |
Mylan Pharmaceuticals | Phase 1 |
Pharmacology for ACCURETIC
Drug Class | Angiotensin Converting Enzyme Inhibitor Thiazide Diuretic |
Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
Physiological Effect | Increased Diuresis |
US Patents and Regulatory Information for ACCURETIC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-001 | Dec 28, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-002 | Dec 28, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-003 | Dec 28, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ACCURETIC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-002 | Dec 28, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-001 | Dec 28, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-002 | Dec 28, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-003 | Dec 28, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-001 | Dec 28, 1999 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ACCURETIC
See the table below for patents covering ACCURETIC around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Germany | 3176029 | ⤷ Sign Up | |
Hungary | 183602 | PROCESS FOR PRODUCING 1,2,3,4-TETRAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID'S SUBSTITUTED ACYL DERIVATIVES | ⤷ Sign Up |
Ireland | 812097 | ⤷ Sign Up | |
Spain | 505960 | ⤷ Sign Up | |
Japan | S5788164 | SUBSTITUTED ACYL DERIVATIVE OF 1,2,3,4- TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ACCURETIC
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0480717 | 98C0025 | Belgium | ⤷ Sign Up | PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215 |
0454511 | 99C0009 | Belgium | ⤷ Sign Up | PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015 |
0096157 | SPC/GB95/011 | United Kingdom | ⤷ Sign Up | SPC/GB95/011:, EXPIRES: 20060930 |
0503785 | CA 2011 00026 | Denmark | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216 |
0454511 | SPC/GB99/008 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |